Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on tumor vaccines.

F K Stevenson1

  • 1Molecular Immunology Group, Southampton University Hospitals, UK.

International Journal of Clinical & Laboratory Research
|January 1, 1992
PubMed
Summary

Cancer vaccination harnesses the immune system to fight tumors. Advances in immunology and molecular biology are making tumor vaccination a promising treatment strategy, especially for B-cell tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early stages in the ontogeny of small B-cell lymphomas: genetics and microenvironment.

Journal of internal medicine·2017
Same author

IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.

Leukemia·2016
Same author

Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.

Leukemia·2014
Same author

Idiotypes and diseases.

Immunology today·2014
Same author

Chronic lymphocytic leukaemia and normal B lymphopoiesis.

Immunology today·2014
Same author

DNA fusion vaccines against B-cell tumors.

Methods in molecular medicine·2011

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Cancer vaccination is a long-standing therapeutic goal, aiming to utilize the host's immune system for sustained tumor cell destruction.
  • Past limitations included poor understanding of tumor antigens and immune cell mechanisms against cancer growth.

Purpose of the Study:

  • To review recent advancements in molecular biology and immunology that are advancing cancer vaccination strategies.
  • To highlight the potential of cancer vaccination as a forefront treatment approach for various tumors.
  • To discuss findings from B-cell tumor vaccination studies, focusing on idiotype as a tumor antigen.

Main Methods:

  • Review of recent developments in molecular biology and immunology relevant to cancer vaccination.
  • Analysis of clinical evidence regarding the host's intrinsic ability to control tumor growth.
  • Exploration of strategies involving biological modifiers and in vitro manipulation of effector cells.

Main Results:

  • Developments in molecular biology and immunology are improving our understanding of tumor antigens and immune pathways.
  • Studies in B-cell tumors using idiotype as a specific tumor antigen show promising results and identify challenges.
  • Clinical evidence suggests the host possesses mechanisms to control tumor growth, with some tumors remaining dormant.

Conclusions:

  • Cancer vaccination is emerging as a key strategy for treating diverse tumors, driven by scientific progress.
  • Understanding tumor antigens and immune mechanisms is crucial for effective vaccination.
  • Combining specific vaccination with non-specific immune stimulation may overcome tumor evasion tactics.

Related Experiment Videos